Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients.
周二，Eledon Pharmicals Inc（纳斯达克股票代码：ELDN）宣布，研究者主导的临床试验的第一位参与者已接受胰岛细胞移植，并正在接受tegoprubart治疗，以预防1型糖尿病患者的胰腺胰岛细胞移植排斥反应。
The company also reported updated data from its ongoing Phase 1b trial as of April 2024 from 13 participants, demonstrating that tegoprubart is generally safe and well-tolerated and supports tegoprubart's potential to protect organ function in patients undergoing kidney transplantation.
该公司还报告了截至2024年4月正在进行的1b期试验的最新数据，这些数据来自13名参与者，这表明tegoprubart总体上是安全的，耐受性良好，并支持tegoprubart在保护接受肾脏移植的患者器官功能方面的潜力。
Aggregate mean estimated glomerular filtration rate (eGFR) – a measure of kidney function – measured above 60 mL/min/1.73m2 at all reported time points after day 30.
在第30天之后的所有报告时间点，累计平均肾小球滤过率（eGFR）（衡量肾脏功能的指标）均高于60 mL/min/1.73m2。
Two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year.
两名受试者在移植后接受了12个月的治疗，并且每年的平均表皮生长因子均超过90 mL/min/1.73m2。
To date, three subjects discontinued the study because of hair loss and fatigue, viral infection, and rejection, respectively.
迄今为止，有三名受试者分别因脱发和疲劳、病毒感染和排斥反应而停止了这项研究。
There have been no cases of graft loss or death.
没有移植物流失或死亡的案例。
Eledon is currently conducting a Phase 1b trial, the Phase 2 BESTOW trial, and a Long-Term Safety and Efficacy extension study to evaluate tegoprubart for the prevention of organ rejection in kidney transplant patients.
Eledon目前正在进行一项1b期试验、BESTOW二期试验和一项长期安全性和有效性扩展研究，以评估tegoprubart在预防肾移植患者器官排斥反应方面的作用。
Concurrently, Eledon Pharmaceuticals announced a private placement of approximately $50 million, offering 13.1 million shares at $2.37 per share and pre-funded warrants at $2.369 per underlying share, which are exercisable to purchase 7.99 million shares.
同时，Eledon Pharmicals宣布进行约5000万美元的私募配售，以每股2.37美元的价格发行1,310万股股票，以每股标的2.369美元的价格发行预先筹集资金的认股权证，可行使购买799万股股票。
HC Wainwright suggests that islet cell transplantation could be a promising way to reverse type 1 diabetes by restoring metabolic control without relying on insulin injections. The analyst highlights tegopruibart's potential to decrease or replace intensive anti-rejection drugs without causing side effects.
HC Wainwright认为，通过在不依赖胰岛素注射的情况下恢复代谢控制，胰岛细胞移植可能是逆转1型糖尿病的一种有前途的方法。该分析师强调了tegopruibart在不引起副作用的情况下减少或替代强效抗排斥药物的潜力。
HC Wainwright reiterates the Buy rating, and with increased confidence in tegoprubart's probability of advancement into a pivotal study, it has raised the price target from $13 to $16.
HC Wainwright重申了买入评级，随着人们对tegoprubart进入关键研究的可能性的信心增强，该公司已将目标股价从13美元上调至16美元。
The analyst continues to look for the potential signing of a licensing collaboration agreement, including an upfront payment worth up to $100 million, for further development and commercialization of tegoprubart around the 2025 timeframe as a future catalyst.
该分析师继续寻找签署许可合作协议的可能性，包括价值高达1亿美元的预付款，用于在2025年前后进一步开发和商业化tegoprubart，以此作为未来的催化剂。
Price Action: ELDN shares are down 9.63% at $2.21 at last check Tuesday.
价格走势：周二最后一次检查时，ELDN股价下跌9.63％，至2.21美元。